A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF JK07 IN ADULTS WITH CHRONIC HEART FAILURE (RENEU-HF)

Registry ID

JK07.2.01

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

SALUBRIS BIOTHERAPEUTICS, INC.

Start date

2024-05-15

Last update

2024-03-13

Conditions

• CHRONIC HEART FAILURE

Related clinical trials

• EASI-HF REDUCED - A PHASE III DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP SUPERIORITY TRIAL TO EVALUATE EFFICACY AND SAFETY OF THE COMBINED USE OF ORAL VICADROSTAT (BI 690517) AND EMPAGLIFLOZIN COMPARED WITH PLACEBO AND EMPAGLIFLOZIN IN PARTICIPANTS WITH SYMPTOMATIC CHRONIC HEART FAILURE (HF: NYHA II-IV) AND LEFT VENTRICULAR EJECTION FRACTION (LVEF) < 40%
• A PHASE III, RANDOMISED, OPEN-LABEL, BLINDED ENDPOINT, COMPARATIVE TRIAL OF FERRIC DERISOMALTOSE VERSUS NO INTRAVENOUS IRON IN IRON-DEFICIENT SUBJECTS WITH SYMPTOMATIC CHRONIC HEART FAILURE
• A PHASE III, RANDOMISED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFECT OF BALCINRENONE/DAPAGLIFLOZIN, COMPARED WITH DAPAGLIFLOZIN, ON THE RISK OF HEART FAILURE EVENTS AND CARDIOVASCULAR DEATH IN PATIENTS WITH HEART FAILURE AND IMPAIRED KIDNEY FUNCTION
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3540378 IN ADULTS WITH WORSENING CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF OMECAMTIV MECARBIL ON MORTALITY AND MORBIDITY IN SUBJECTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
• A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL GROUP EFFICACY AND SAFETY STUDY OF ALLOGENIC MESENCHYMAL PRECUSOR CELLS (CEP-41750) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY

View on source registry